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Identiﬁcation of cell-type-speciﬁc mutations in nodal T-cell
lymphomas
TB Nguyen1,2,3, M Sakata-Yanagimoto1,4,5, Y Asabe1, D Matsubara6, J Kano7, K Yoshida8, Y Shiraishi9, K Chiba9, H Tanaka9, S Miyano9,
K Izutsu10,11, N Nakamura12, K Takeuchi13, H Miyoshi14, K Ohshima14, T Minowa15, S Ogawa8, M Noguchi7 and S Chiba1,4,5
Recent genetic analysis has identiﬁed frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A),
isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic
T-cell lymphoma and peripheral T-cell lymphoma, not otherwise speciﬁed. We examined the distribution of mutations in these
subtypes of mature T-/natural killer cell neoplasms to determine their clonal architecture. Targeted sequencing was performed for
71 genes in tumor-derived DNA of 87 cases. The mutations were then analyzed in a programmed death-1 (PD1)-positive population
enriched with tumor cells and CD20-positive B cells puriﬁed by laser microdissection from 19 cases. TET2 and DNMT3A mutations
were identiﬁed in both the PD1+ cells and the CD20+ cells in 15/16 and 4/7 cases, respectively. All the RHOA and IDH2 mutations
were conﬁned to the PD1+ cells, indicating that some, including RHOA and IDH2 mutations, being speciﬁc events in tumor cells.
Notably, we found that all NOTCH1 mutations were detected only in the CD20+ cells. In conclusion, we identiﬁed both B- as well as
T-cell-speciﬁc mutations, and mutations common to both T and B cells. These ﬁndings indicate the expansion of a clone after
multistep and multilineal acquisition of gene mutations.
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INTRODUCTION
Nodal T-cell lymphomas are subtypes of mature T-/natural killer-cell
neoplasms, including angioimmunoblastic T-cell lymphoma (AITL);
nodal peripheral T-cell lymphoma (PTCL) with T follicular helper
(TFH) phenotype; peripheral T-cell lymphoma, not otherwise
speciﬁed (PTCL-NOS), and follicular T-cell lymphoma. Among them,
AITL is a distinct subtype, accounting for 16.0–28.7% of all mature T-/
natural killer-cell neoplasms.1–3 AITL is characterized by speciﬁc
clinical features, including generalized lymphadenopathy, high fever,
skin rash and autoimmune-like manifestations. AITL tumor cells
share characteristics with TFH cells, expressing B-cell lymphoma
protein 6, a transcription factor; C-C motif chemokine receptor 5, a
chemokine receptor; C-X-C motif ligand 13, a chemokine; and
programmed death-1 (PD1), a member of the CD28 costimulatory
membrane receptor family.4,5 AITL tissues display prominent
inﬁltration of inﬂammatory cells, follicular dendritic cell meshwork
formation and branching vascular structures. Some nodal T-cell
lymphomas exhibit several features reminiscent of AITL, although
they do not show the typical morphology of AITL (nodal PTCL with
TFH phenotype).6,7 The massive inﬁltration of inﬂammatory cells in
AITL has been explained by cytokines and chemokines being
released from TFH-like tumor cells.4
Recurrent gene mutations have been identiﬁed in nodal T-cell
lymphomas, including those in ten-eleven translocation 2 (TET2) in
20–83%, isocitrate dehydrogenase 2 (IDH2) in 0–45%, and ras
homolog family member A (RHOA) in 17–71%, depending on
the subtypes and DNA methyltransferase 3A (DNMT3A) in
approximately 30%, independent of the subtypes.8–13 Mutations
in TET2 encoding a methylcytosine dioxygenase and those in
DNMT3A encoding a DNA methyltransferase presumably result in
epigenetic abnormalities in nodal T-cell lymphomas. IDH2 muta-
tions also affect epigenetic modiﬁcations by inhibiting TET and
histone demethylation enzymes through production of 2-
hydroxyglutarate.14 Mutations in RHOA encoding a small GTPase
are almost always located at the hotspot site, resulting in
conversion from glycine to valine at the seventeenth position of
the RHOA protein (G17V RHOA mutation). The G17V RHOA
mutants could not be converted to an active GTP-bound form,
although the downstream signaling of the G17V RHOA mutants in
nodal T-cell lymphomas development has yet to be clariﬁed.8,9,13
TET2 and DNMT3A mutations are proposed to arise in
hematopoietic stem/progenitors upstream of T-lineage commit-
ment. This hypothesis is based on the fact that identical TET2 and
DNMT3A mutations were found in both tumor tissues and
apparently normal blood cells in some AITL and PTCL-NOS
patients.8,10,15–17 In contrast, the origins of the G17V RHOA
mutation remain to be elucidated: it may be a tumor-speciﬁc
event, considering that the allele frequencies of G17V RHOA
mutations were lower than those of TET2 mutations and that G17V
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RHOA mutations were found in only CD4+T lymphocytes in 1 AITL
and 1 PTCL-NOS case.8
Here we describe the clonal architecture of nodal T-cell
lymphomas by determining the distribution of mutations in
enriched tumor cells and inﬁltrated B cells.
MATERIALS AND METHODS
Patients and samples
Samples, obtained from 87 patients (Supplementary Table S1) with AITL
(n=48), nodal PTCL with TFH phenotype (n=5) and either of PTCL-NOS or
of nodal PTCL with TFH phenotype (PTCL-NOS/nodal PTCL with TFH
Figure 1. Targeted sequencing result of 87 nodal T-cell lymphoma samples. TET2-, RHOA-, IDH2- and DNMT3A-mutated cases are indicated by
blue, red, orange and green boxes, respectively. Other recurrently mutated genes are in purple. The laser-microdissected samples are
indicated in red letters.
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phenotype, n=34),5 were used after approval was obtained from the local
ethics committees of all the participating institutes.
Genomic DNA was extracted from 56 fresh frozen samples using the
Puregene DNA Blood Kit (Qiagen, Hilden, Germany) and 31 periodate-lysine-
paraformaldehyde (PLP)-ﬁxed frozen samples using the QIAamp DNA FFPE
Tissue Kit (Qiagen).
Targeted sequencing
Targeted sequencing was performed for 71 genes, which are listed in
Supplementary Table S2. Sixty-one of the genes were previously screened
by whole-exome sequencing,8 while 6 were the family genes of those
whose mutations were identiﬁed by the whole-exome sequencing. The
other four genes were deemed susceptible to mutations in PTCLs on the
basis of the mutational proﬁles of other lymphoid malignancies.18–23 All
the exons of the selected genes were captured by use of a SureSelect
Target Enrichment Kit (Agilent, Santa Clara, CA, USA) and then massively
sequenced using HiSeq2000 (Illumina, Santa Clara, CA, USA). For each
sample, all the sequencing reads were aligned to hg19 using BWA version
0.5.8 with default parameters. After all the duplicated reads and the low-
quality reads and bases were removed, the allele frequencies of single-
nucleotide variants and indels at each genomic position were calculated
by enumerating the relevant reads using SAMtools (http://www.htslib.org).
Initially, all the variants showing allele frequencies 40.02 were extracted
and annotated using ANNOVAR24,25 for further consideration, if they were
found in46 reads of410 total reads and appeared in both the positive-
and the negative-strand reads. All synonymous variants and known single-
nucleotide polymorphisms in public and private databases, including
dbSNP131, the 1000 genomes project as of 2012/05/21 and our in-house
database, were removed. To exclude germline variants, nonsynonymous
variants were excluded when the allele frequencies were from 0.45 to 0.55.
Candidate mutations were validated by amplicon-based deep sequencing
using Ion PGM (Life Technologies, Carlsbad, CA, USA) and/or Sanger
sequencing (see below).
In the cohort of 87 cases, 79 were analyzed for RHOA, TET2, DNMT3A and
IDH2 mutations, and the results of this analysis were described in the
previous paper.7 Now, eight were new cases. We re-analyzed all the 87
samples for targeted sequencing of 71 genes.
Amplicon-based sequencing
The libraries were prepared using the Ion Plus Fragment Library Kit according
to the protocol for preparing short amplicon libraries (Life Technologies).
Brieﬂy, PCR amplicons were ligated to the barcode adapters and P1 adapters
and then ampliﬁed. The ampliﬁed libraries were quantitated by quantitative
PCR with the Ion Library Quantitation Kit according to the manufacturer’s
instructions (Life Technologies). The libraries were then subjected to deep
sequencing on the Ion Torrent PGM platform according to the standard
protocol for 300 base-pair single-end reads (Life Technologies). The data
were analyzed using Variant Caller 3.4 (Life Technologies).
Immunohistochemistry
PLP-ﬁxed frozen samples were cut in a cryostat at −22 °C into 5-μm sections
and mounted on PEN-Membrane slides (Leica, Wetzlar, Germany). The tissue
sections were stained with mouse anti-human PD1 (NAT105 ab52587,
Abcam, Cambridge, UK) and anti-human CD20cy (clone L26, Dako, Michigan,
MI, USA) antibodies, diluted 1:2000 and 1:1000, respectively, and detected by
use of the Envision+ Dual Link System-HRP (Dako). The tissue sections were
then counterstained with hematoxylin (Mayer’s hematoxylin, Muto Pure
Chemical, Tokyo, Japan) for 20 s at room temperature. After staining, tissue
sections were dehydrated with ethanol and dried at room temperature
before laser microdissection (LMD).
LMD, DNA extraction and PCR
Nineteen of the 87 cases (13 AITL, 1 nodal PTCL with TFH phenotype and
PTCL-NOS/nodal PTCL with TFH phenotype) were analyzed by LMD, which
was performed using LMD7000 (Leica). The cells being positive for either PD1
or CD20 were dissected and collected into 0.2-ml PCR tubes (Takara, Shiga,
Japan) containing 20 μl of distilled water. Stained cells at approximately
100 000 μm2 were dissected and collected for each sample. Genomic DNA
was extracted using the QIAamp DNA PFFE Tissue Kit (Qiagen) following the
manufacturer’s protocol. Then 1 μl of DNA was used for PCR under the
following conditions: 95 °C for 15 min, 60 °C for 4 min, 72 °C for 4 min, 35 to
40 cycles at 95 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min, and 72 °C for
10 min using the AmpliTaq Gold 360 Kit (Applied Biosystems, Foster City, CA,
USA) with each primer set (Supplementary Table S6). PCR amplicons were
used for amplicon-based sequencing and Sanger sequencing.
IgH gene rearrangement analysis and subcloning of the PCR
product
Multiplex PCR assays were used to detect the clonality of B cells according to
the European BIOMED-2 collaborative study.26 PCR products migrating at the
expected size were extracted and sequenced using the Sanger method.
Subcloning was performed if the Sanger sequencing indicated a polyclonal
Table 1. Targeted sequencing result of 87 nodal T-cell lymphoma
samples
Gene AITL
(n=48)
Nodal PTCL with
TFH phenotype
(n= 5)
PTCL-NOS/nodal
PTCL with TFH
phenotype (n=34)
All
(n= 87)
n % n % n % n %
TET2 36 75 5 100 19 55.9 60 69
RHOA 33 68.8 5 100 3 8.8 41 47.1
DNMT3A 11 22.9 1 20 11 32.4 23 26.4
IDH2 13 27.1 0 0 0 0 13 14.9
NAV2 0 0 0 0 4 11.8 4 4.6
ODZ1 2 4.2 1 20 1 2.9 4 4.6
COL19A1 1 2.1 0 0 2 5.9 3 3.4
FAT2 1 2.1 0 0 2 5.9 3 3.4
MTERFD3 2 4.2 0 0 1 2.9 3 3.4
NOTCH1 3 6.3 0 0 0 0 3 3.4
B2M 0 0 0 0 2 5.9 2 2.3
HMCN1 1 2.1 0 0 1 2.9 2 2.3
LAMA2 0 0 0 0 2 5.9 2 2.3
MLL2 0 0 0 0 2 5.9 2 2.3
TET3 2 4.2 0 0 0 0 2 2.3
LYN 2 4.2 0 0 0 0 2 2.3
EBF2 1 2.1 0 0 1 2.9 2 2.3
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; nodal PTCL
with TFH phenotype, nodal peripheral T-cell lymhoma with T follicular
helper phenotype; PTCL-NOS, peripheral T-cell lymhoma, not otherwise
speciﬁed.
Table 2. Mutation proﬁles of 19 laser microdissected samples
Gene AITL
(n= 13)
Nodal PTCL with
TFH phenotype
(n=1)
PTCL-NOS/nodal
PTCL with TFH
phenotype (n= 5)
All
(n=19)
n % n % n % n %
TET2 12 92.3 1 100 3 60 16 84.2
RHOA 9 69.2 1 100 0 0 10 52.6
DNMT3A 6 46.2 1 100 0 0 7 36.8
IDH2 4 30.8 0 0 0 0 4 21.1
NAV2 0 0 0 0 1 20 1 5.3
ODZ1 1 7.7 0 0 0 0 1 5.3
COL19A1 1 7.7 0 0 1 20 2 10.5
FAT2 1 7.7 0 0 0 0 1 5.3
MTERFD3 1 7.7 0 0 0 0 1 5.3
NOTCH1 3 23.1 0 0 0 0 3 15.8
B2M 0 0 0 0 1 20 1 5.3
HMCN1 1 7.7 0 0 0 0 1 5.3
MLL2 0 0 0 0 1 20 1 5.3
TET3 1 7.7 0 0 0 0 1 5.3
LYN 1 7.7 0 0 0 0 1 5.3
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; nodal PTCL with
TFH phenotype, nodal peripheral T-cell lymhoma with T follicular helper
phenotype; PTCL-NOS, peripheral T-cell lymhoma, not otherwise speciﬁed.
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background by use of the pGEM-T Easy Vector System I (Promega, Madison,
WI, USA). At least 12 colonies were picked up and sequenced to conﬁrm the
clonal expansion. The sequence results were analyzed using the IMGT tools27
and aligned to the closest match with the germline IGHV segment.
Sequencing results with a germline identity of o98% were regarded as
mutated and vice versa according to previous study.28
RESULTS
Novel recurrent mutations in nodal T-cell lymphomas
Targeted sequencing for 71 genes was performed in 87 samples
(Supplementary Table S1), including AITL (n= 48), nodal PTCL with
TFH phenotype (n= 5) and PTCL-NOS/nodal PTCL with TFH
phenotype (n= 34). TET2, DNMT3A, RHOA and IDH2 mutations
were identiﬁed in 60 (68.7%), 23 (26.4%), 41 (47.1%) and 13
(14.9%) of 87 cases, respectively (Figure 1, Table 1, Supplementary
Table S3). The mutational proﬁles of these 4 genes in 79 of the 87
samples are described elsewhere.7
Thirty-four novel recurrent mutations were identiﬁed in 13 of
the 71 (18.3%) genes and in 24 of the 87 (26.4%) cases (Figure 1,
Table 1 and Supplementary Table S4). Mutations in genes associated
with lymphoid malignancies, for example, Notch homolog 1,
translocation-associated (NOTCH1), β2 microglobulin (B2M) and
mixed-lineage leukemia 2 (MLL2) were identiﬁed in 3, 2 and
Figure 2. RHOA mutations are speciﬁc to PD1+ cells. (a) An example of the immunostaining pattern for PD1 and CD20 in AITL. Left, PD1+ cells;
right, CD20+ cells. (b) Sequences of G17V RHOA mutations in whole tumor, PD1+ cells and CD20+ cells. The numeric values indicate allele
frequencies of mutations deﬁned by amplicon-based deep sequencing. The AITL samples are indicated in black letters. The nodal PTCL with
TFH phenotype sample is indicated in red letters *: RHOA c.A51T:p.G17V, silent mutation. The ﬁlled and dashed red arrows indicate mutations
and no mutations, respectively.
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2 cases, respectively. Mutations in FAT atypical cadherin 2 (FAT2),
a gene associating with several cancers, and those in TET3, a
member of the TET gene family, were identiﬁed in 3 and 2 cases,
respectively.
Nineteen of the 87 samples were analyzed by the use
of LMD (Figure 1). The frequencies of TET2, DNMT3A, RHOA
and IDH2 mutations in the laser-microdissected samples
were similar to those found in the entire cohort (TET2
mutations, 16/19 (84.1%); DNMT3A mutations, 7/19 (36.8%);
RHOA mutations, 10/19 (52.6%) and IDH2 mutations, 4/19
(21.1%)) (Table 2). A total of 26 TET2 mutations were found
in 16 cases, while 2 TET2 mutations were found in 10 samples
each (Supplementary Table S5). NOTCH1 and COL19A1
mutations were identiﬁed in 3 and 2 cases, respectively. Other
Figure 3. Distributions of TET2/DNMT3A/RHOA/IDH2/NOTCH1 mutations and IgH VDJ status. Allele frequencies of TET2/DNMT3A/RHOA/IDH2/
NOTCH1 mutations in whole tumor, PD1+ cells and CD20+ cells are shown. The blue boxes represent positive TET2mutations; the green boxes,
positive DNMT3A mutations; the red boxes, positive RHOA mutations; the orange boxes, positive IDH2 mutations; the purple boxes, positive
NOTCH1 mutations; the yellow boxes, no mutations; and the white boxes, not examined. The numeric values indicate allele frequencies of
mutations deﬁned by deep sequencing, except for that in the box surrounded by bold red lines which was estimated by Sanger sequencing.
IgH VDJ status indicates the IgH VDJ rearrangement status in whole-tumor-derived DNA. The AITL samples are indicated in black letters. The
nodal PTCL with TFH phenotype sample is indicated in red letters. The PTCL-NOS/nodal PTCL with TFH phenotype sample is indicated in blue
letters. MC, monoclonality; OC, oligoclonality; Pos: positivity was evaluated only by Sanger sequencing. Multiple TET2 mutations were
identiﬁed in PTLC2, 8, 60, 63, 77, 136, 121, 123, 127 and 129.
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gene mutations, including NAV2, ODZ1, FAT2, MTERFD3, B2M,
HMCN1, MLL2, TET3 and LYN, were identiﬁed in a single
case each.
Speciﬁc existence of G17V RHOA mutations in tumor cell-enriched
cells of nodal T-cell lymphomas
Previously, we reported that G17V RHOA mutations were detected
by ﬂow cytometry only in CD4-positive (CD4+) cells but not in
other cell lineages puriﬁed from the skin tumor of a PTCL-NOS
patient and the pleural effusion cells of an AITL patient.8 These
preliminary results suggested that the G17V RHOA mutation may
speciﬁcally exist in mature CD4+ T cells in PTCL-NOS and AITL. To
gain further insight into the origin of the G17V RHOA mutation, we
examined the mutation in laser-microdissected PD1+ and CD20+
B cells, which were assumed to be enriched and depleted in tumor
cells, respectively, in 10 nodal T-cell lymphomas (1 nodal PTCL
with TFH phenotype and 9 AITL cases). The G17V RHOA mutation
was detected only in the PD1+ cells but not in the CD20+ cells in
all 10 cases (Figure 2). The allele frequencies of the G17V RHOA
mutations in the dissected PD1+ cells were substantially higher
than those in the matched whole tumor samples in 7 of the 10
cases. The efﬁciency of mutation allele enrichment was not
substantial in three cases (PTCL63, PTCL78 and PTCL127). In these
cases, PD1+ cell selection was not sucessful enough to purify the
tumor cells because of the presumed abundance of PD1+ non-
tumor cells or the very high tumor cell content before the
selection. Additionally, using ﬂow cytometry, we found an AITL
case showing that the G17V RHOA mutation existed in PD1+CD4+
cells sorted from bone marrow mononuclear cells (Supplementary
Figure S2). This ﬁnding strongly supports our hypothesis that the
acquisition of the G17V RHOA mutation is a speciﬁc event in
TFH cells.
Figure 4. Distribution of newly identiﬁed gene mutations in nodal T-cell lymphomas. The results of Sanger sequencing and/or amplicon-
based deep sequencing for some newly identiﬁed gene mutations in whole tumor, PD1+ cells and CD20+ cells are shown. The numeric values
indicate allele frequencies of mutations deﬁned by deep sequencing. The AITL samples are indicated in black letters. The PTCL-NOS/nodal
PTCL with TFH phenotype sample is indicated in blue letters. NA, not analyzed by deep sequencing. The ﬁlled and dashed red arrows indicate
mutations and no mutations, respectively.
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Distribution of TET2, IDH2 and DNMT3A mutations
We and others have previously reported that TET2 and DNMT3A
mutations were found in apparently normal blood cells, including
bone marrow mononuclear cells, and in immature progenitors and
blood cells of various lineages isolated from peripheral blood of a
few PTCL patients.7,9,15–17 We examined the distribution of TET2,
IDH2 and DNMT3A mutations in PD1+ and CD20+ cells. Twenty of
the 26 TET2 mutations were identiﬁed in both the PD1+ and the
CD20+ cells (Supplementary Table S7), and 15 of the 16 TET2-
mutated samples had at least one mutation in both the PD1+ and
the CD20+ cells (Figure 3). Concomitantly, DNMT3A mutations
were identiﬁed in both the PD1+ and CD20+ cells in four of the
seven DNMT3A-mutated samples (Figure 3, Supplementary Table S8).
In myeloid malignancies, TET2 and IDH2 mutations are known to
be mutually exclusive.14,29 However, we and others reported that
IDH2 mutations often coexist with TET2 mutations in PTCL.8,10,30
IDH2 mutations were identiﬁed in PD1+ cells but not in CD20+
cells in all 4 TET2- and IDH2-comutated samples (PTCL8, PTCL61,
PTCL63 and PTCL70) (Figure 3). Each of these samples had at least
one TET2 mutation in both the PD1+ and CD20+ cells and the
G17V RHOA mutation only in the PD1+ cells. That is, TET2, IDH2
and G17V RHOA mutations coexisted in the PD1+ cells in these
cases. In addition, we also found the coexistence of IDH2, TET2 and
G17V RHOA mutations in PD1+CD4+ cells sorted from the bone
marrow mononuclear cells of an AITL patient (Supplementary
Figure S2).
B-cell-speciﬁc mutations in nodal T-cell lymphomas
To clarify the cellular origin of newly identiﬁed gene mutations, we
also checked the distribution of these mutations in PD1+ and
CD20+ cells (Table 2). We identiﬁed B2M, COL19A1, HMCN1,
MTERFD3 and TET3 mutations only in PD1+ cells but not in CD20+
cells. COL19A1, LYN, NAV2 and NOTCH2NL mutations were
identiﬁed in both the PD1+ and CD20+ cells (Figure 4).
Interestingly, three NOTCH1 and one FAT2, MLL2 and ODZ1
mutations each were found only in the CD20+ but not in the PD1+
cells in four samples (PTCL 63, PTCL70, PTCL78 and PTCL128)
(Figure 5). Especially, all three NOTCH1 mutations identiﬁed by
Figure 5. B-cell-speciﬁc mutations in nodal T-cell lymphomas. The results of Sanger sequencing and/or amplicon-based deep sequencing for
some newly identiﬁed gene mutations in whole tumor, PD1+ cells and CD20+ cells are shown. The numeric values indicate allele frequencies
of mutations deﬁned by deep sequencing. The AITL samples are indicated in black letters. The PTCL-NOS/nodal PTCL with TFH phenotype
sample is indicated in blue letters. NA, not analyzed by deep sequencing. The ﬁlled and dashed red arrows indicate mutations and no
mutations, respectively. NOTCH1 is marked by red letters because this is repetitive.
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targeted sequencing were identiﬁed only in the CD20+ cells with
high allele frequencies. The NOTCH1 gene encodes a transmem-
brane protein. One of the NOTCH1 mutations was a frameshift
mutation residing in the PEST domain of the Notch1 protein.
This would be an activating mutation, because deletion of the
PEST domain enhances Notch signaling after ligand binding.19 The
other two mutations were located in one of the epidermal growth
factor-like and in the ankyrin repeat domains (Supplementary
Figure S1). One of the NOTCH1-mutated samples simultaneously
had two TET2 mutations and G17V RHOA mutation (PTCL 63,
Supplementary Table S9). In this case, both TET2 mutations were
detected in both the PD1+ and CD20+ cells, while the G17V RHOA
mutation was conﬁned to the PD1+ cells. We used the multiplex
PCR method26 to also check the clonality of immunoglobulin
genes in the samples with B-cell-speciﬁc mutations. Interestingly,
only one sample showed monoclonal rearrangement while the
others showed oligoclonal rearrangement (Table 3).
DISCUSSION
By determining the distribution of the mutations, we elucidated
the clonal architecture of nodal T-cell lymphomas. RHOA muta-
tions were identiﬁed only in PD1+ cells in 100% cases, while TET2
and DNMT3A mutations were identiﬁed in both the PD1+ cells and
CD20+, tumor-cell-depleted cells in the majority of cases. In
addition, IDH2 mutations were actually found only in the PD1+
cells and coexisted with TET2 mutations. These data suggest that,
in nodal T-cell lymphoma development, multistep tumorigenesis
may progress in association with the differentiation of blood cells/
lymphocytes. Surprisingly, some of the mutations resided in a
B-cell-speciﬁc manner.
Recent genetic studies have revealed that, in several hemato-
logical cancers, several gene mutations existed in preleukemic
hematopoietic cells as well as in tumor cells;31 examples are
TET2 and/or DNMT3A mutations in acute myeloid leukemia32–34
and NOTCH1 and SF3B1 mutations in chronic lymphocytic
leukemia.35,36 Moreover, somatic mutations have been demon-
strated in elderly individuals without hematological malignancies:
DNMT3A, ASXL1, and TET2 mutations frequently observed in
hematological malignancies were the most frequent in these
cohorts.37–40 Similarly, our data indicated that in nodal T-cell
lymphomas, premalignant cells having TET2 and/or DNMT3A
mutations may differentiate not only into T-lineage tumor cells
but also into B cells. In contrast, the G17V RHOA mutations
speciﬁcally existed in the T cells of nodal T-cell lymphomas in all
13 cases (11 cases have been described in this paper, while 2 were
previously described elsewhere8), indicating that the G17V RHOA
mutation is the event after the B- and T-cell speciﬁcation. This
could happen right after the T/B speciﬁcation, after differentiation
into TFH cells or even after malignant transformation establishing
a subclone. One possibility is that the G17V RHOA mutation occurs
in TET2-mutated premalignant cells and facilitates the selective
differentiation of TET2-mutated premalignant cells into tumor cells
with the TFH phenotype. This needs to be proven in the future.
IDH2 mutations were also speciﬁcally identiﬁed in the tumor-
cell-enriched cells, suggesting that IDH2 mutations are also tumor-
cell-speciﬁc events in AITL, although the number of samples was
not large enough to allow a deﬁnite conclusion. We have
previously showed that the IHD2-mutated cases were almost a
subcohort of G17V RHOA-mutated cases.8 This result could be
interpreted that the acquisition of IDH2 mutations may be the
event occurring after the acquisition of RHOA mutation and thus
the IDH2-mutated cells may, at least in some cases such as PTCL70,
constitute a subclone in the RHOA-mutated clone. TET2- and IDH2-
comutated AITL samples were reported to have more extensive
histone modiﬁcation proﬁles than those with TET2 mutations
without an IDH2 mutation, while the difference in genome-wide
cytosine methylation proﬁles between these samples was only
moderate.30
Our data showed that B cells that have inﬁltrated AITL tissues
also have gene mutations: the multilineal mutations represented
by those in TET2 and DNMT3A, and B-cell-speciﬁc mutations
represented by those in NOTCH1 and other genes. Monoclonal or
oligoclonal expansion of B cells has been found in up to 30% of
AITL cases.41–43 Furthermore, approximately 10% of AITL cases
develop B-cell malignancies during their clinical course.42,44–47
Some lymphoma cells are infected by Epstein–Barr virus. In such
cases, Epstein–Barr virus is proposed to contribute to the
transformation of B cells.45,46 This hypothesis, however, needs to
be re-evaluated because Epstein–Barr virus was not detected in
a substantial proportion of B-cell malignancies accompanying
AITL.48 TET2 mutations are found in diffuse large B-cell
lymphomas.49 Tet2-deﬁcient mice show the expansion of both
B- and T-cell lineages in addition to prominent myeloproliferation.15
Combinational loss of Tet1 and Tet2 provokes B-cell malignancies
in mice.50 Activating NOTCH1 mutations were reported in diffuse
large B-cell lymphomas,51 chronic lymphocytic leukemia,52 mantle
cell lymphoma22 and follicular lymphoma.53 In our cohort, all three
NOTCH1 mutations were deﬁned only in B cells with very high
allele frequencies (Figure 5, Supplementary Table S9) and two of
the three samples showed oligoclonality of B cells (Table 3). This
implies that the origin of NOTCH1 mutation is earlier than the
acquisition of hypermutation of the CDR3 region in the
immunoglobulin gene. Anyway, acquisition of these mutations
in B-cell lineage may account for the frequent occurrence of B-cell
lymphomas in AITL. Moreover, our data alert us to the need for
careful interpretation of the mutational proﬁles of PTCLs because
some of the mutations may not exist in tumor cells.
In conclusion, our ﬁndings illustrate the concept of multistep
and multilineal tumorigenesis in nodal T-cell lymphomas
(Supplementary Figure S3). Understanding the pathogenesis will
lead us to better management of nodal T-cell lymphomas in
future.
Table 3. VDJ rearrangement status of B-cell clones in B-cell-speciﬁc mutated samples
Sample Diagnosis Number of colonies having the identical
VDJ gene usage/total number of colonies
analyzed
Common VDJ gene
usage
Identity of
V gene (%)
Amino-acid sequences of junctions
PTCL63 AITL 2/12 V3-21/D2-2/J5 72.2 CARSTQTYYQLLWNG#NWFDPWa
PTCL74 AITL NAb V1-2/J1 or J2 or J3 84.4 Not identiﬁed at http://www.imgt.org
PTCL78 AITL 2/12 V3-23/J6/D4-17 72.2 CAKGNDYGDSYYYGMDVW
2/12 V3/J6/D3-10 77.2 CARDRGYYYYGMDVW
PTCL126 PTCL-NOS/nodal PTCL
with TFH phenotype
2/12 V6-1/J6/D3-3 71.0 CARTTPSTIFGVVTAGYYYYGMDVW
aOut of frame junction. bNA, not applicable because direct sequencing demonstrated monoclonality.
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